USA / Importing Drugs from Canada: America’s Zombieland Sequel
Market access and pricing expert Barbara Jaszewski outlines the issues inherent in the USA importing drugs from…
Writing in the March edition of DIA’s Global Forum magazine, Judith Glennie examines the findings of Health Canada's consultation with Canadians on what a national strategy for high-cost rare disease…
Market access and pricing expert Barbara Jaszewski outlines the issues inherent in the USA importing drugs from…
Clint Sharples, CEO of Heritage Cannabis, gives a potted history of the medical cannabis industry in Canada, its…
As the only country in the world to boast a universal healthcare system that does not cover prescription drugs,…
Dr Thomas D. Madden, CEO and founder of Acuitas Therapeutics, shares the story behind their involvement in Pfizer and BioNTech’s COVID-19 vaccine, the numerous applications of the company’s proprietary lipid nanoparticle (LNP) delivery technology, as well as the growth strategy of the Canadian company. pharmaboardroom · The bright future of mRNA technology w/Acuitas Therapeutics
Up-to-date data and infographics on the Canadian pharma market including an overview of market dynamics,…
Fasken Canada’s Dara Jospe and Denis Douville examine Canada’s COVID-19 vaccine strategy, from the…
Canada is the only developed country with a universal healthcare system that does not provide universal coverage of…
Pamela Fralick of Innovative Medicines Canada (IMC) advocates for a collaborative multi-stakeholder approach to…
As the only country in the world to boast a universal healthcare system that does not cover prescription drugs,…
The latest news from Canadian pharma including deals for J&J’s and Novavax’s COVID-19 vaccines, an abrupt…
Diabetes Canada’s Jan Hux outlines how her organization has been able to shift from small, local programs to…
As Canada’s emergent medical cannabis industry develops at home, several of the country’s leading companies are…
The research areas in which Canada has the potential to excel are numerous, one being the world of genomics. The…
Despite its relative youth, Canada’s medical cannabis industry is already presenting some of the characteristics…
Dr Neil Cashman looks at the potential impact of US FDA approval for Biogen’s aducanumab on the search for…
Marina Vasiliou took the reins as managing director of Biogen Canada in November 2017 after a long and varied…
Writing in the March edition of DIA’s Global Forum magazine, Judith Glennie examines the findings of Health…
With cost-cutting measures exacerbating an already fraught regulatory process, the Canadian generics industry is…
Market access and pricing expert Barbara Jaszewski outlines the issues inherent in the USA importing drugs from…
When the European Medicines Agency (EMA) relocated from London to Amsterdam after the UK announced its decision to…